Zhejiang East Asia Pharmaceutical Completes Establishment of Subsidiary

MT NewswiresMar 11 15:16

Zhejiang East-Asia Pharmaceutical (605177.SH): plans to invest 60 million yuan to establish a wholly-owned subsidiary in Zhejiang Shan Heng.

On March 10, Gelonghui reported that Zhejiang East-Asia Pharmaceutical (605177.SH) announced that to further enhance and improve the overall industry development layout and strengthen the competitiveness of the existing pharmaceutical industry pipeline, the company has invested 60 million yuan in its own funds to establish a wholly-owned subsidiary, Zhejiang Shan Heng, in Sanmen County, Zhejiang Province, accounting for 100% of the registered capital of Zhejiang Shan Heng. The establishment of this wholly-owned subsidiary will help enrich the industry pipeline, enhance overall competitiveness, and seek business expansion opportunities. The company continuously enriches its product pipeline around the mid-to-long-term Global Strategy of "centered on Active Pharmaceutical Ingredient, extending forward and backward." The company is in Zhejiang.

Gelonghui FinanceMar 10 15:54

East Asia Pharmaceutical: Dongfang Jincheng International Credit Evaluation Co., Ltd.\'s notice on the 2024 performance pre-loss of Zhejiang East Asia Pharmaceutical Co., Ltd.

SZSIFeb 11 00:00 · Announcements

Zhejiang East-Asia Pharmaceutical (605177.SH): Not involved in the HPV vaccine business.

According to a statement on the interactive platform on January 20, Gelonghui reported that Zhejiang East-Asia Pharmaceutical (605177.SH) does not engage in the HPV vaccine business.

Gelonghui FinanceJan 20 16:08

Zhejiang East-Asia Pharmaceutical (605177.SH): Luliconazole Active Pharmaceutical Ingredient has obtained the Active Pharmaceutical Ingredient registration certificate from South Korea.

On January 20, Gelonghui reported that Zhejiang East-Asia Pharmaceutical (605177.SH) announced the receipt of the Active Pharmaceutical Ingredient registration certificate from the South Korea Ministry of Food and Drug Safety (South Korea MFDS) for Luliconazole, which is used to treat superficial fungal infections caused by sensitive fungi such as tinea pedis, tinea corporis, and tinea cruris. It can also be used for cutaneous candidiasis and tinea versicolor. The company's Luliconazole Active Pharmaceutical Ingredient has obtained the registration certificate in South Korea, marking the eligibility for entry into the South Korean market, which will positively impact the company's expansion into the South Korean pharmaceutical market and help promote the sales of Luliconazole Active Pharmaceutical Ingredient in other overseas markets.

Gelonghui FinanceJan 20 15:33

East Asia Pharmaceutical: East Asia Pharmaceutical 2024 Annual Results Forecast Announcement

SZSIJan 17 00:00 · Announcements